Genome-edited adult stem cells: Next-generation advanced therapy medicinal products
MetadatosAfficher la notice complète
AuteurBenabdellah, Karim; Sánchez Hernández, Sabina; Aguilar González, Araceli; Maldonado Pérez, Noelia; Cortijo Gutierrez, Marina; Ramos Hernández, Iris; Tristán Manzano, María; Martín, Francisco
Adult stem cellsCRISPRElectroporationGene delivery systems in vivo or in vitroGene therapyHematopoietic stem cells (HSCs)Mesenchymal stem cells (MSCs)Pluripotent hemopoietic stem cells
Benabdellah, K., Sánchez‐Hernández, S., Aguilar‐González, A., Maldonado‐Pérez, N., Gutierrez‐Guerrero, A., Cortijo‐Gutierrez, M., ... & Martin, F. (2020). Genome‐edited adult stem cells: Next‐generation advanced therapy medicinal products. Stem Cells Translational Medicine, 9(6), 674-685. [Doi: 10.1002/sctm.19-0338]
PatrocinadorEuropean Regional Development Fund (FEDER), Grant/Award Numbers: PI18/01610, PI18/00330, PI18/00337, grants PI12/01097; Spanish ISCIII Health Research Fund
Over recent decades, gene therapy, which has enabled the treatment of several incurable diseases, has undergone a veritable revolution. Cell therapy has also seen major advances in the treatment of various diseases, particularly through the use of adult stem cells (ASCs). The combination of gene and cell therapy (GCT) has opened up new opportunities to improve advanced therapy medicinal products for the treatment of several diseases. Despite the considerable potential of GCT, the use of retroviral vectors has major limitations with regard to oncogene transactivation and the lack of physiological expression. Recently, gene therapists have focused on genome editing (GE) technologies as an alternative strategy. In this review, we discuss the potential benefits of using GE technologies to improve GCT approaches based on ASCs. We will begin with a brief summary of different GE platforms and techniques and will then focus on key therapeutic approaches that have been successfully used to treat diseases in animal models. Finally, we discuss whether ASC GE could become a real alternative to retroviral vectors in a GCT setting.